PubMed:21943124 / 976-1112 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T10","span":{"begin":0,"end":136},"obj":"Sentence"},{"id":"T10","span":{"begin":0,"end":136},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Based on the known pathogenesis of Apert syndrome, the chimeric FGFR2 protein is predicted to act in a dominant gain-of-function manner."}

{"project":"PubCasesORDO","denotations":[{"id":"AB3","span":{"begin":35,"end":49},"obj":"ORDO:87"}],"namespaces":[{"prefix":"ORDO","uri":"http://www.orpha.net/ORDO/Orphanet_"}],"text":"Based on the known pathogenesis of Apert syndrome, the chimeric FGFR2 protein is predicted to act in a dominant gain-of-function manner."}